Vir BiotechnologyVIR
VIR
About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Employees: 408
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
96% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 27
12% more funds holding
Funds holding: 207 [Q4 2024] → 231 (+24) [Q1 2025]
3.48% more ownership
Funds ownership: 64.47% [Q4 2024] → 67.94% (+3.48%) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 68
3% more call options, than puts
Call options by funds: $1.87M | Put options by funds: $1.81M
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
7% less capital invested
Capital invested by funds: $652M [Q4 2024] → $604M (-$48.1M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
168%
upside
Avg. target
$17.50
235%
upside
High target
$21
302%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Joseph Stringer | 168%upside $14 | Buy Reiterated | 22 May 2025 |
Goldman Sachs Paul Choi | 302%upside $21 | Buy Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 3 articles about VIR published over the past 30 days
Negative
Market Watch
4 days ago
20 stocks you should avoid — no matter how well the market does
These hard-to-short stocks are likely to lose money, researchers found.
Neutral
Business Wire
2 weeks ago
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be ar.
Neutral
Business Wire
3 weeks ago
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Inv.
Neutral
Business Wire
1 month ago
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived f.
Neutral
Business Wire
1 month ago
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% (3/18) and 2.
Positive
Seeking Alpha
1 month ago
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is projected to surpass $1.05 billion by 2034. VIR-5518 and VIR-5500 are dual-masked HER2 and PSMA T-cell engagers being developed to target solid tumors; The current status of these candidates is that dose-escalation for both are ongoing.
Neutral
Seeking Alpha
1 month ago
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Nick Gasic - Leerink Partners Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. Joseph Stringer - Needham & Company Operator Hello.
Negative
Zacks Investment Research
1 month ago
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago.
Neutral
Business Wire
1 month ago
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 marked significant progress in our mission of powering the immune system to transform lives," said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "We successfully dosed the first patient in our ECLIPSE Phase 3 registrational program for hepatitis delta, a.
Neutral
Business Wire
1 month ago
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biote.
Charts implemented using Lightweight Charts™